<DOC>
	<DOCNO>NCT00636090</DOCNO>
	<brief_summary>The purpose study look genetic change RAD001 cause prostate cancer cell change relate patient ' response RAD001 treatment .</brief_summary>
	<brief_title>Molecular , Genetic , Genomic Assessments From Patients Treated With RAD001</brief_title>
	<detailed_description>This correlative science study minimum risk assessment tumor plasma sample collect part Phase II clinical trial RAD001 patient HRPC . Prior enrollment time sign consent Phase II trial , patient approach participate correlative science study . Patients agree participate assign separate study number use identify molecular , genetic , genomic biomarker assessment use tumor plasma sample . Clinical outcome result accompany Phase II trial use correlative assessment study , however , result correlative science study keep separate assessment report clinical trial .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients must enrol clinical study entitle : A Single Arm , Phase II Study RAD001 Patients Metastatic , HormoneRefractory Prostate Cancer time enrollment onto study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>